Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04264767 · ClinicalTrials.gov registry record
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
A clinical trial of Cancer and Solid Tumor, sponsored by Nucleix.
- Completed
- Registry status
- 800
- Enrollment target
- 3
- Study locations
NCT04264767 is a study of Cancer and Solid Tumor that has completed, run by Nucleix. The registered enrollment target is 800 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04264767, a study of Cancer and Solid Tumor, has completed, sponsored by Nucleix.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
- 3
- Study locations
Study Summary
Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.
Conditions Studied
Interventions
- PROCEDURE Blood collection
Study Locations (3)
California
- Los Angeles Hematology Oncology Medical Group - Wilson Terrace - Glendale
- Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices - Los Angeles
Other
- Sourasky Medical Center - Tel Aviv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2021-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04264767
The ClinicalTrials.gov registry entry for NCT04264767 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Nucleix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood collection is the first listed.
NCT04264767 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT04264767 about?
NCT04264767 is a clinical study titled "Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA". Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test whic...
What is the current status of trial NCT04264767?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2019-04-17. Estimated completion is 2021-01-30.
What conditions does trial NCT04264767 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Hematologic Neoplasms.
What interventions are being tested in trial NCT04264767?
The interventions under investigation include: Blood collection (PROCEDURE).
Who is sponsoring clinical trial NCT04264767?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04264767 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.